A Columbia study shows a simple smell test and memory exam can predict cognitive decline as accurately as costly brain imaging, offering a more affordable and accessible way to assess dementia.
The amyloid hypothesis "was so compelling that it triggered the pharmaceutical industry to act,” said Scott Small, MD, professor of neurology and psychiatry at Columbia.
Our neurons are endowed with a completely separate set of mechanisms that are dedicated to active forgetting, says Scott A. Small, a professor of neurology and psychiatry at Columbia.
A new study has found that performing well on two brief tests measuring cognitive ability and ability to identify odors indicates very low risk for Alzheimer’s.
Dr. Kathleen M. Pike highlights Dementia Reimagined, a book that can help us understand the complex interplay of biology and environment in putting us at risk for dementia.
A clinical trial conducted by Columbia University and Duke University suggest that donepezil may not improve cognitive performance in people at risk for Alzheimer’s disease who also had depression.
Dr. John Mann said this study used much more sophisticated statistical techniques than previous studies to rule out an association between lithium in groundwater and lower risk of bipolar disorder.
Researchers at Columbia University Medical Center and New York State Psychiatric Institute may have discovered a way to use a patient’s sense of smell to treat Alzheimer’s disease before it develops.
People living with HIV and their loved ones should be aware of the symptoms of HIV-associated dementia, so the appropriate diagnostic investigation and treatment can be initiated as soon as possible.